🔗 Share this article

While America undertakes sweeping revisions to its immunization recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus shots during the global health crisis and has zeroed in on alleged fatalities following COVID-19 immunization in her recent tenure at the FDA.

Planned Overhauls to Pediatric Immunization Program

Health officials planned to announce major changes to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, it is understood – a major change that would put the US at odds with many the international standard with little proof for public health gain. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to run the office this year.

A Shift at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending certain pediatric shot schedules in the US so as to align more like Denmark, a society with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – traditionally the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Background

Dr. Høeg has little discernible track record in medication creation, approval processes or management, which has been customary for past directors of the CBER. She has served at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of the center would “grasp regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who headed CBER have had.”

CDER has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“Many people just pays attention on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There is also a biosimilars program, over-the-counter program and more, and all of those have to be looked after,” Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major leadership element to the job, which manages in excess of 5,000 personnel. “It is a enormous leadership role, if you do it right,” she added.

Agency Reaction and Disputed Programs

In response to inquiries about Dr. Høeg's qualifications and whether this selection represents more teamwork among regulatory chiefs on vaccines, a press secretary stated that the “concerns are based on incorrect assumptions”.

“This background aligns with the duties of her job,” the representative said, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious rapid drug-approval program that reportedly worried her former heads. “How are these medications being chosen for this fast-track system? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards laxer rules of most medications, aside from vaccines.”

Established History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, past, Howard have noted. She published a research paper using unverified crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Included in her “desired changes” for the incoming federal leadership encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she said after the election on a podcast. At the FDA, Høeg has allegedly suggested barring young men from getting COVID-19 vaccinations.

“She is an complete true believer who begins with her conclusions and tailors the evidence to accommodate the evidence in a extremely deceptive, fraudulent manner,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|